Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS)

Maturitas

Volumn 89, Issue , 2016, Pages 63-72

  Armeni, Eleni ^a   Lambrinoudaki, Irene ^a   Ceausu, Iuliana ^c   Depypere, Herman ^d   Mueck, Alfred ^e   Pérez López, Faustino R ^f   Schouw, Yvonne T Van Der ^g   Senturk, Levent M ^h   Simoncini, Tommaso ⁱ   Stevenson, John C ^j   Stute, Petra ^k   Rees, Margaret ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

^e UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^f UNIVERSITY OF ZARAGOZA   (Spain)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ UNIVERSITY OF PISA   (Italy)

^j ROYAL BROMPTON HOSPITAL   (United Kingdom)

^k UNIVERSITY OF BERN   (Switzerland)

more..

Author keywords

Genitourinary syndrome of menopause; Hormone therapy; Hot flushes; Menopause; Osteoporosis; Women

Indexed keywords

BAZEDOXIFENE; CALCIUM; CLONIDINE; CONJUGATED ESTROGEN; ESTRADIOL; ESTRIOL; ESTROGEN; FLIBANSERIN; FOLLITROPIN; FRAGILE X MENTAL RETARDATION PROTEIN; GABAPENTIN; GESTAGEN; GLUCOSE; LEVONORGESTREL; LUBRICATING AGENT; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; NORETHISTERONE; OSPEMIFENE; PHOSPHORUS; PROLACTIN; PROMESTRIENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; THYROID PEROXIDASE ANTIBODY; THYROTROPIN; TIBOLONE; VITAMIN D;

ALCOHOL CONSUMPTION; ALTERNATIVE MEDICINE; AMENORRHEA; ANTHROPOMETRY; ARTICLE; BLOATING; BONE DENSITY; BREAST CANCER; BREAST DENSITY; BREAST EXAMINATION; BREAST TENDERNESS; CALCIUM BLOOD LEVEL; CARDIOVASCULAR RISK; COGNITION; COGNITIVE DEFECT; DIASTOLIC BLOOD PRESSURE; DIET; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; EARLY MENOPAUSE; ENDOMETRIUM CANCER; ESTRADIOL BLOOD LEVEL; EXERCISE; FAMILY HISTORY; FEMALE; FLUID RETENTION; FOLLITROPIN BLOOD LEVEL; FOLLOW UP; FRAGILITY FRACTURE; GLUCOSE BLOOD LEVEL; GROUPS BY AGE; GYNECOLOGIC DISEASE; GYNECOLOGICAL EXAMINATION; HEADACHE; HORMONAL THERAPY; HUMAN; HYPERPROLACTINEMIA; HYPOACTIVE SEXUAL DESIRE DISORDER; LIFESTYLE; LONGEVITY; LOW LEVEL LASER THERAPY; LUTEINIZING HORMONE BLOOD LEVEL; MAMMOGRAPHY; MEDICAL HISTORY; MENOPAUSAL SYNDROME; MENOPAUSE; METRORRHAGIA; MOOD DISORDER; MUSCLE MASS; MUSCLE STRENGTH; NUTRITION; OSTEOPOROSIS; OVARIAN RESERVE; OVARIECTOMY; OVARY FUNCTION; PHOSPHATE BLOOD LEVEL; PHYSICAL ACTIVITY; POSTMENOPAUSE OSTEOPOROSIS; PREGNANCY; PREMATURE OVARIAN FAILURE; PROLACTIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTIVE HEALTH; SARCOPENIA; SIDE EFFECT; SLEEP DISORDER; SMOKING HABIT; STELLATE GANGLION BLOCK; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; THYROID FUNCTION TEST; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; UROGENITAL SYSTEM; VAGINA ATROPHY; VASOMOTOR DISORDER; VENOUS THROMBOEMBOLISM; WOMEN'S HEALTH; HORMONE SUBSTITUTION; MEDICAL SOCIETY;

DIET; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; LIFE STYLE; MENOPAUSE; SOCIETIES, MEDICAL; WOMEN'S HEALTH;

EID: 84965175418     PISSN: 03785122     EISSN: 18734111     Source Type: Journal    
DOI: 10.1016/j.maturitas.2016.04.013     Document Type: Article

References (84)

1. Eurostat Mortality and Life Expectancy Statistics 2015 (accessed 02.02.16) http://ec.europa.eu/eurostat/statistics-explained/index.php/Mortality-and-life-expectancy-statistics
2. ONS National life tables, United Kingdom, 2011-2013 Stat. Bull. 2014 (accessed 02.02.16) http://www.ons.gov.uk/ons/rel/lifetables/national-life-tables/2010-2012/sty-facts-about-le.html
3. J.L. Shifren, and M.L. Gass The North American Menopause Society recommendations for clinical care of midlife women Menopause 21 10 2014 1038 1062
4. M. Neves-E-Castro, M. Birkhauser, G. Samsioe, and et al. EMAS position statement: the ten point guide to the integral management of menopausal health Maturitas 81 1 2015 88 92
5. National Institute for Health and Care Excellence (NICE) Menopause: Diagnosis and Management (NG23). 2015 https://www.nice.org.uk/guidance/ng23/resources/menopause-diagnosis-and-management-1837330217413 (accessed 02.02.16).
6. C.A. Stuenkel, S.R. Davis, A. Gompel, and et al. Treatment of symptoms of the menopause: an Endocrine Society clinical practice guideline J. Clin. Endocrinol. Metab. 100 11 2015 3975 4011
7. F.M. Jane, and S.R. Davis A practitioner's toolkit for managing the menopause Climacteric 17 5 2014 564 579
8. J.L. Shifren, and M.L. Gass The North American Menopause Society recommendations for clinical care of midlife women Menopause 21 10 2014 1038 1062
9. S. Vujovic, M. Brincat, T. Erel, and et al. EMAS position statement: managing women with premature ovarian failure Maturitas 67 1 2010 91 93
10. S.D. Harlow, M. Gass, J.E. Hall, and et al. STRAW 10Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging Menopause 19 4 2012 387 395
11. R. Tal, O. Tal, and et al. Antimullerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis Fertil. Steril. 103 1 2015 119 130
12. D. Dewailly, C.Y. Andersen, and et al. The physiology and clinical utility of anti-Mullerian hormone in women Hum. Reprod. Update 20 3 2014 370 385
13. B. Leader, and V.L. Baker Maximizing the clinical utility of antimullerian hormone testing in women's health Curr. Opin. Obstet. Gynecol. 26 4 2014 226 236
14. N.E. Avis, S.L. Crawford, G. Greendale, and et al. Study of Women's Health Across the Nation: duration of menopausal vasomotor symptoms over the menopause transition JAMA Int. Med. 175 4 2015 531 539
15. E.W. Freeman, M.D. Sammel, and R.J. Sanders Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort Menopause 21 9 2014 924 932
16. D.J. Portman, M. Gass, and L. Vulvovaginal Atrophy terminology consensus conference panel. genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women's sexual health and the north american menopause society Maturitas 79 3 2014 349 354
17. S. Palacios, C. Castelo-Branco, H. Currie, and et al. Update on management of genitourinary syndrome of menopause: a practical guide Maturitas 82 3 2015 308 313
18. J.L. Shaver, and N.F. Woods Sleep and menopause: a narrative review Menopause 22 8 2015 899 915
19. R.A. Lobo, S.R. Davis, T.J. De Villiers, and et al. Prevention of diseases after menopause Climacteric 17 5 2014 540 556
20. J.G.Z. van Uffelen, and W.J. Brown BMI and longevity in women: a time for reflection? Maturitas 67 4 2010 294 295
21. S.-H. Chang, T.S. Beason, and et al. A systematic review of body fat distribution and mortality in older people Maturitas 72 3 2012 175 191
22. G. Mancia, R. Fagard, K. Narkiewicz, and et al. ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J. 34 28 2013 2159 2219
23. I. Graham, D. Atar, and et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur. J. Cardiovasc. Prev. Rehabil. 14 2 2007 E1 40
24. J. Perk, G. De Backer, and et al. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) Eur. Heart J. 33 13 2012 1635 1701
25. E. Dreisler, L.G. Poulsen, and et al. EMAS clinical guide: assessment of the endometrium in peri- and postmenopausal women Maturitas 75 2 2013 181 190
26. M. Hickey, D. Ameratunga, and et al. Unscheduled bleeding in continuous combined hormone therapy users Maturitas 70 4 2011 400 403
27. D. Saslow, D. Solomon, and et al. American cancer society, american society for colposcopy and cervical pathology, and american society for clinical pathology screening guidelines for the prevention and early detection of cervical cancer Cancer J. Clin. 62 3 2012 147 172
28. Public Health England. Cervical screening: programme overview. https://www.gov.uk/guidance/cervical-screening-programme-overview, 2015 (accessed 02.02.16).
29. European Cervical Cancer Association, http://www.ecca.info (accessed 02.02.16).
30. M. Rees, F.R. Pérez-López, I. Ceausu, and et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy Maturitas 73 2 2012 171 174
31. American College of Obstetricians and Gynecologists (ACOG). Breast cancer screening. Pract. Bull., 118 (2 Pt. 1), 2011, 372-382.
32. US Preventive Services Breast Cancer Screening Final Recommendations 2016 (accessed 02.02.16) www.USPreventiveServicesTaskForce.org
33. K.C. Oeffinger, E.H. Fontham, R. Etzioni, and et al. Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society JAMA 314 15 2015 1599 1614
34. E. Altobelli, and A. Lattanzi Breast cancer in the European Union: an update of screening programmes as of March 2014 (review) Int. J. Oncol. 45 5 2014 1785 1792
35. National Institute for Health and Care Excellence Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer. NICE guidelines (CG164), June 2013. http://www.nice.org.uk/guidance/cg164 (accessed 02.02.16).
36. H. Depypere, J. Desreux, F.R. Pérez-López, and et al. EMAS position statement: individualized breast cancer screening versus population-based mammography screening programmes Maturitas 79 4 2014 481 486
37. R.T. Chlebowski, G.L. Anderson, A.K. Aragaki, and R. Prentice Breast cancer and menopausal hormone therapy by race/ethnicity and body mass index J. Natl. Cancer Inst. 108 2 2015 10.1093/jnci/djv327 (pii: djv327)
38. J. Compston, C. Bowring, A. Cooper, and et al. Diagnosis and management of osteoporosis in postmenopausal women and older men in the UK: National Osteoporosis Guideline Group (NOGG) update 2013 Maturitas 75 4 2013 392 396
39. Garvan Institute Fracture risk calculator. Garvan Institute, Sydney, Australia, 2010. http://garvan.org.au/promotions/bone-fracture-risk/calculator (accessed 02.02.16).
40. J. Hippisley-Cox, and C. Coupland Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study BMJ 344 2012 e3427
41. M. Brincat, J. Calleja-Agius, C.T. Erel, and et al. EMAS position statement: bone densitometry screening for osteoporosis Maturitas 68 1 2011 98 101
42. F. Cosman, S.J. de Beur, M.S. LeBoff, and et al. 1; Clinician's guide to the prevention and treatment of osteoporosis Osteoporosis Int. 25 10 2014 2359 2381
43. A.J. Cruz-Jentoft, J.P. Baeyens, and et al. Sarcopenia: european consensus on definition and diagnosis: report of the european working group on sarcopenia in older people Age Ageing 39 4 2010 412 423
44. I. Lambrinoudaki, I. Ceausu, H. Depypere, and et al. EMAS position statement: diet and health in midlife and beyond Maturitas 74 1 2013 99 104
45. NICE guidelines PH56 Vitamin D: increasing supplement use in at-risk groups. https://www.nice.org.uk/guidance/ph56, 2014 (accessed 02.02.16).
46. I.R. Reid, and M.J. Bolland Calcium risk-benefit updated - new WHI analyses Maturitas 77 1 2014 1 3
47. M.J. Woodward, C.W. Lu, and et al. The exercise prescription for enhancing overall health of midlife and older women Maturitas 82 1 2015 65 71
48. A.J. Daley, A. Thomas, A.K. Roalfe, and et al. The effectiveness of exercise as treatment for vasomotor menopausal symptoms: randomised controlled trial BJOG 122 4 2015 565 575
49. T.J. de Villiers, M.L. Gass, C.J. Haines, J.E. Hall, R.A. Lobo, D.D. Pierroz, and M. Rees Global Consensus Statement on menopausal hormone therapy Maturitas 74 4 2013 391 392
50. H.N. Hodis, W.J. Mack, and V.W. Henderson et al; ELITE Research Group: vascular effects of early versus late postmenopausal treatment with estradiol N. Engl. J. Med. 374 13 2016 1221 1231
51. S. Palacios, H. Currie, T.S. Mikkola, and E. Dragon Perspective on prescribing conjugated estrogens/bazedoxifene for estrogen-deficiency symptoms of menopause: a practical guide Maturitas 80 4 2015 435 440
52. G. Formoso, E. Perrone, S. Maltoni, and et al. Short and long term effects of tibolone in postmenopausal women Cochrane Database Syst. Rev. 2 2012 CD008536
53. J.V. Pinkerton, and N. Santoro Compounded bioidentical hormone therapy: identifying use trends and knowledge gaps among US women Menopause 22 9 2015 926 936
54. F.Z. Stanczyk, J.P. Hapgood, S. Winer, and D.R. Mishell Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects Endocr. Rev. 34 2 2013 171 208
55. D.F. Archer, T. Schmelter, M. Schaefers, C. Gerlinger, and K. Gude A randomized, double-blind, placebo-controlled study of the lowest effective dose of drospirenone with 17β-estradiol for moderate to severe vasomotor symptoms in postmenopausal women Menopause 21 3 2014 227 235
56. G.A. Bachmann, M. Schaefers, A. Uddin, and W.H. Utian Lowest effective transdermal 17 beta-estradiol dose for relief of hot flushes in postmenopausal women: a randomized controlled trial Obstet. Gynecol. 110 4 2007 771 779
57. North American Menopause Society Statement on continuing use of systemic hormone therapy after age 65 Menopause 22 7 2015 693
58. L. Lindh-Astrand, M. Bixo, A.L. Hirschberg, I. Sundström-Poromaa, and M. Hammar A randomized controlled study of taper-down or abrupt discontinuation of hormone therapy in women treated for vasomotor symptoms Menopause 17 1 2010 72 79
59. T.S. Mikkola, P. Tuomikoski, H. Lyytinen, P. Korhonen, F. Hoti, P. Vattulainen, M. Gissler, and O. Ylikorkala Increased cardiovascular mortality risk in women discontinuing postmenopausal hormone therapy J. Clin. Endocrinol. Metab. 100 12 2015 4588 4594
60. G. Mintziori, I. Lambrinoudaki, and et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms Maturitas 81 3 2015 410 413
61. H. Joffe, K.A. Guthrie, A.Z. LaCroix, and et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial JAMA Int. Med. 174 7 2014 1058 1066
62. FDA Approves the First Non-hormonal Treatment for Hot Flashes Associated with Menopause (accessed 02.02.16) http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm359030.htm
63. C.M. Kelly, D.N. Juurlink, T. Gomes, and et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study BMJ 8 340 2010 Feb c693
64. L. Bordeleau, K.I. Pritchard, C.L. Loprinzi, and et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors J. Clin. Oncol. 28 35 2010 5147 5152
65. T. Guttuso Jr. Stellate ganglion block for treating hot flashes: a viable treatment option or sham procedure? Maturitas 76 3 2013 221 224
66. D.R. Walega, L.H. Rubin, S. Banuvar, L.P. Shulman, and P.M. Maki Effects of stellate ganglion block on vasomotor symptoms: findings from a randomized controlled clinical trial in postmenopausal women Menopause 21 8 2014 807 814
67. J.A. Simon, and I. Dhanuka Flibanserin for postmenopausal women - are they really that different? Maturitas 82 4 2015 325 327
68. S. Mirkin, and J.H. Pickar Selective estrogen receptor modulators (SERMs): a review of clinical data Maturitas 80 1 2015 52 57
69. J. Hutchinson-Colas, and S. Segal Genitourinary syndrome of menopause and the use of laser therapy Maturitas 82 4 2015 342 345
70. S. Palacios, M. Brincat, C.T. Erel, M. Gambacciani, I. Lambrinoudaki, M.H. Moen, and et al. EMAS clinical guide: selective estrogen receptor modulators for postmenopausal osteoporosis Maturitas 71 2 2011 194 198
71. M. McClung, S.T. Harris, and et al. Bisphosphonate therapy for osteoporosis: benefits, risks, and drug holiday Am. J. Med. 126 1 2013 13 20
72. P. Anagnostis, and J.C. Stevenson Bisphosphonate drug holidays-when, why and for how long? Climacteric 18 Suppl. 2 2015 32 38
73. R. Josse, A. Khan, and et al. Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis Curr. Med. Res. Opin. 29 3 2013 205 216
74. J.A. Kanis, E.V. McCloskey, and et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporos. Int. 24 1 2013 23 57
75. L. Cianferotti, F. D'Asta, and et al. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis Ther. Adv. Musculoskelet Dis. 5 3 2013 127 139
76. EMA. European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions. 21 February, 2014. http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2014/02/WC500161971.pdf (accessed 02.02.16).
77. A.V. Uihlein, and B.Z. Leder Anabolic therapies for osteoporosis Endocrinol. Metab. Clin. North Am. 41 3 2012 507 525
78. A.R. Genazzani, B.S. Komm, and J.H. Pickar Emerging hormonal treatments for menopausal symptoms Expert Opin. Emerg. Drugs 20 1 2015 31 46
79. B. Bernick, and S. Mirkin A new solubilized vaginal estradiol in a VagiCap™ for the treatment of vaginal atrophy Maturitas 82 3 2015 324
80. Clinicaltrials. Gov., Multicenter study to evaluate safety and efficacy of WC-3011 in postmenopausal women. https://clinicaltrials.gov/ct2/show/NCT01816139, 2016 (accessed 02.02.16).
81. S. Mirkin, J.M. Amadio, B.A. Bernick, J.H. Pickar, and D.F. Archer 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review Maturitas 81 1 2015 28 35
82. Clinicaltrials. Gov., Dehydroepiandrosterone (DHEA) + acolbifene against vasomotor symptoms (hot flushes) in postmenopausal women. https://clinicaltrials.gov/ct2/show/NCT01452373, 2016 (accessed 02.02.16).
83. N.M. Iniguez-Ariza, and B.L. Clarke Bone biology, signaling pathways, and therapeutic targets for osteoporosis Maturitas 82 2 2015 245 255
84. R.R. Recker, C.T. Benson, T. Matsumoto, and et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density J. Bone Miner.Res. 30 2 2015 216 224